240 related articles for article (PubMed ID: 32902858)
1. Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.
Nazha B; Goyal S; Chen Z; Engelhart A; Carlisle JW; Beardslee TJ; Gill H; Odikadze L; Liu Y; Mishra MK; Ramalingam SS; Owonikoko TK
Cancer; 2020 Dec; 126(23):5040-5049. PubMed ID: 32902858
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer.
Peravali M; Ahn J; Chen K; Rao S; Veytsman I; Liu SV; Kim C
Oncologist; 2021 Aug; 26(8):694-700. PubMed ID: 33844354
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer.
Li L; Xu C; Wang W; Zhang Q
Clin Respir J; 2024 May; 18(5):e13763. PubMed ID: 38717297
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
7. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Yoshida H; Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Hosoya K; Itotani R; Sakamori Y; Kim YH; Hirai T
Eur J Cancer; 2021 Feb; 144():317-325. PubMed ID: 33385948
[TBL] [Abstract][Full Text] [Related]
9. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R
Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer.
Enomoto T; Tamiya A; Matsumoto K; Adachi Y; Azuma K; Inagaki Y; Kouno S; Taniguchi Y; Saijo N; Okishio K; Atagi S
Clin Transl Oncol; 2021 Mar; 23(3):582-590. PubMed ID: 32661824
[TBL] [Abstract][Full Text] [Related]
12. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV
Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Hsu JC; Lin JY; Hsu MY; Lin PC
PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
[TBL] [Abstract][Full Text] [Related]
14. Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.
Nelli F; Virtuoso A; Giannarelli D; Fabbri A; Giron Berrios JR; Marrucci E; Fiore C; Ruggeri EM
Curr Oncol; 2023 Sep; 30(9):8117-8133. PubMed ID: 37754504
[TBL] [Abstract][Full Text] [Related]
15. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
17. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
Furuya N; Nishino M; Wakuda K; Ikeda S; Sato T; Ushio R; Tanzawa S; Sata M; Ito K
Thorac Cancer; 2021 Mar; 12(5):613-618. PubMed ID: 33448648
[TBL] [Abstract][Full Text] [Related]
18. Non-small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?
Li Y; Gong B; Guo Y; Liu W; Chen C; Jiang S; Pan F; Song J; Yang L; Zhou G
BMC Cancer; 2024 Apr; 24(1):535. PubMed ID: 38671373
[TBL] [Abstract][Full Text] [Related]
19. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Ono K; Ono H; Toi Y; Sugisaka J; Aso M; Saito R; Kawana S; Aiba T; Odaka T; Matsuda S; Saito S; Narumi A; Ogasawara T; Shimizu H; Domeki Y; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
[TBL] [Abstract][Full Text] [Related]
20. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
